The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Follow-up Of Women On A Randomised Clinical Trial Of Adjuvant Docetaxel And Doxorubicin For Node Positive Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$113,250.00
Summary
This project is testing the use of a drug docetaxel in the post-operative (adjuvant) treatment of women with breast cancer and involved lymph nodes (N+). Until recently the drug doxorubicin was the most active chemotherapy drug for breast cancer, but more recently a new group of chemotherapy drugs called taxanes were identified. One taxane called docetaxel may be even more effective than doxoubicin. Using available treatments that include doxorubicin based chemotherapy, approximately half the wo ....This project is testing the use of a drug docetaxel in the post-operative (adjuvant) treatment of women with breast cancer and involved lymph nodes (N+). Until recently the drug doxorubicin was the most active chemotherapy drug for breast cancer, but more recently a new group of chemotherapy drugs called taxanes were identified. One taxane called docetaxel may be even more effective than doxoubicin. Using available treatments that include doxorubicin based chemotherapy, approximately half the women with N+ breast cancer experience recurrence of their cancer. It is therefore important to test whether the inclusion of docetaxel in adjuvant therapy can reduce relapses. If docetaxel is to be included, it is also important to test whether it is best to combine it with doxorubicin at the same time (which for safety reasons requires the doses of each drug to be reduced), versus giving them sequentially at full dose. Currently, docetaxel is not approved nor funded for use in early breast cancer in Australia. There are several international trials testing the inclusion of taxanes in the adjuvant therapy of breast cancer. However this trial stands out, because all the women in the trial receive chemotherapy of at least 6 months. In some other trials, testing the possible benefit of adding a taxane, women in the control treatment group (who were randomised not to receive the taxane) received only 3 months of treatment, which makes it difficult to distinguish between longer treatment or addition of the taxane drug. This trial has completed international recruitment of 2890 women who will be carefully followed for 10 years. Australian and New Zealand centers recruited 20% of the women in the trial. After the women have been followed-up for 5 years the results of this trial will be analysed, presented and published and should provide reliable evidence about the potential benefit of adding docetaxel into adjuvant chemotherapy.Read moreRead less
Clinical Trial Of Adjuvant Docetaxel And Doxorubicin For Node Positive Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$185,135.00
Summary
This project is investigating the optimal use of docetaxel and doxorubicin in the treatment of women with breast cancer and involved lymph nodes (N+). Every year 3000 women in Australia, and over 400,000 worldwide are newly diagnosed with N+ breast cancer. Using available treatments more than 60% of these (5 per day in Australia, 4,500 each week worldwide) will die from breast cancer. The efficacy of adjuvant chemotherapy in early breast cancer is well established by the international overview c ....This project is investigating the optimal use of docetaxel and doxorubicin in the treatment of women with breast cancer and involved lymph nodes (N+). Every year 3000 women in Australia, and over 400,000 worldwide are newly diagnosed with N+ breast cancer. Using available treatments more than 60% of these (5 per day in Australia, 4,500 each week worldwide) will die from breast cancer. The efficacy of adjuvant chemotherapy in early breast cancer is well established by the international overview conducted by the Early Breast Cancer Trialist's Collaborative Group (EBCTCG). They have demonstrated the efficacy of adjuvant chemotherapy on reducing mortality and recurrence rates, but current regimens are far from optimal. Docetaxel (Taxotere), a new agent, has effectiveness and manageable side effects in the treatment of advanced breast cancer patients, and can plausibly improve outcomes for patients with early N+ breast cancer by optimal integration into current adjuvant chemotherapy regimens. This clinical trial is designed to compare whether it is advantageous to use docetaxel and-or doxorubicin in combination or sequentially with other currently available chemotherapy drugs.Read moreRead less
Incidence And Prognosis Of Metastatic Breast Cancer: A Population-based Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$97,700.00
Summary
This project will provide the first Australian population-based estimates of metastaticbreast cancer (MBC) incidence and survival in women with an initial diagnosis of early stage cancer that reflect current treatment practices. This evidence will help: women with MBC and their clinicians to make decisions about treatment and plan supportive care; researchers planning trials of MBC therapies, and future planning of cancer services.
Breast And Ovarian Cancer: Beyond Genome Wide Association Studies
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
My research is focused on using genetic approaches to understand the basis of cancer, particularly breast and ovarian cancer. Although many risk factors have been identified for these cancers, they do not lend themselves to primary prevention, except for high risk individuals who opt for prophylactic surgery, and so there is an urgent need to understand the aetiology of these cancers in order to develop better risk prediction algorithms and risk reduction medications.
Integrin Beta3 As A Therapeutic Target For Breast Cancer Metastasis To Bone
Funder
National Health and Medical Research Council
Funding Amount
$431,675.00
Summary
There are limited effective treatments for advanced breast cancer. The project investigates the role of a protein called integrin beta3 in the spread of breast tumours to bone, the most common site of secondary tumour formation (metastasis) in breast cancer patients. We will determine if the presence of integrin beta3 in breast tumours identifies patients at risk of developing bone metastases and test novel drugs against integrin beta3 in mice.
The Landscape Of Cancer Genes And Associations With Prognosis In Breast Cancer Diagnosed In Premenopausal Women
Funder
National Health and Medical Research Council
Funding Amount
$700,512.00
Summary
Using state of the art technology, the purpose of this project is understand the implications of known cancer mutations in breast cancer diagnosed in premenopausal ER-positive breast cancer. Mutations are abnormalities in the DNA of genes that can provide a signal for uncontrolled growth, a hallmark of cancer. The unique aspect of this project is use of tissue samples from patients who were diagnosed with breast cancer at a young age. This information will help us develop new treatments.
Determining The Clinical Relevance Of Intratumour Heterogeneity In Breast Cancer And Its Relationship To Metastases Formation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Breast cancer metastasis is generally an incurable disease, yet it is not well-understood. This project aims to understand how cancer metastasises by using a novel and unique approach of analysing multiple regions from matched primary and metastatic tumours from breast cancer patients. Expected outcomes include identifying predictors of treatment resistance and resultant personalised management and therapeutic strategies to improve survival outcomes of breast cancer patients.
Temporal Trends In The Incidence, Site And Survival Of Metastatic Breast Cancer In Australia
Funder
National Health and Medical Research Council
Funding Amount
$190,494.00
Summary
There have been major advances in breast cancer treatment over the last decade. This project will use information collected from the NSW cancer registry and hospitals to report on changes in the type and risk of breast cancer spread and survival for women with a new diagnosis of breast cancer before and after new treatments introduced since 2005. This information is essential for doctors to provide women with up-to-date information; and for planning appropriate health services and research.
From Transcriptome Metanalysis To Targeted Therapies In Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$483,363.00
Summary
We identified a gene expression signature, a genetic fingerprint, that identifies patients who are affected by very aggressive forms of breast cancer. In this project, we will develop a clinically relevant test that can be used to guide treatment planning against aggressive types of breast cancer to improve survival rates. In addition we will validate new and novel targets for future drug development against these aggressive subtypes.